Digital Look

Welcome to Digital Look++,
you are not logged in

Avacta Group (AVCT)

Pharma and Biotech

44.60p

Trade now with Barclays Stockbrokers

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Jun-23	Interim	11.89	(12.80)	(4.28)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Jul-18	2.76	(10.39)	(9.50)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-19	5.51	(18.05)	(12.98)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	2.14	(18.86)	(7.27)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	2.94	(29.19)	(10.57)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	9.65	(41.46)	(15.48)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-23	22.84	(26.11)	(11.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	26.09	(32.55)	(11.03)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	28.97	(35.15)	(10.37)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.